tbuckley/cabot-search huggingface dataset:
Prognostic value of S100B levels and LDH levels in melanoma patients
Authors: Y. S. Chun, Y. Wang, D. Y. Wang, D. M. McClain, A. Lucci, P. F. Mansfield, J. N. Cormier, M. I. Ross, J. E. Gershenwald, J. E. Lee
Journal: Journal of Clinical Oncology (2008)

9002 Background: The blood level of S100B has been proposed as a melanoma prognostic marker, and LDH has been incorporated into the current AJCC staging system for patients with stage IV melanoma; however, limited data exist regarding their relative utility. We therefore investigated associations between these markers and survival in a large cohort of prospectively followed melanoma patients. Methods: Patients with all stages of disease underwent simultaneous blood draw for LDH and S100B determination. Clinicians were blinded to S100B but not LDH results. Clinical data was obtained from a comprehensive melanoma patient database; all patients underwent standardized evaluation and prospective follow-up. Stage of disease and overall survival (OS) were determined based on the date of blood draw. An S100B level of >0.2 mcg/L and an LDH level of >618 U/L were considered elevated. Results: Paired S100B and LDH levels were obtained from 574 patients (386 stages I-II, 132 stage III, 56 stage IV). S100B was elevated in 87 patients (15%) and LDH was elevated in 44 (8%); 60 patients (69%) with an elevated S100B had a normal LDH. There were strong correlations between stage and both S100B (p<0.0001) and LDH (p<0.0001): elevations of S100B and LDH were seen in 7% and 2% of stages I-II, 15% and 5% stage III, and 71% and 43% of stage IV patients, respectively. After a median follow-up of 14 months, 94 patients (16%) had progressed, and 59 (10%) had died. Both S100B and LDH levels were independent predictors of OS on multivariate analysis (Table). Furthermore, S100B remained an independent predictor of OS in the subset of patients with a normal LDH (p=0.009, HR=2.7, 95% CI 1.3–5.4). Conclusions: S100B provides prognostic information in melanoma patients that is both independent of and complementary to LDH. While additional follow-up will be necessary to determine the utility of S100B in early-stage melanoma, these data suggest S100B may assist the selection of high-risk patients for more intensive follow-up or for adjuvant therapy trials. Association of stage, S100B, and LDH with OS in 574 melanoma patients Prognostic factor Univariate P Multivariate P HR (95% CI) Age 0.2 - - Gender 0.2 - - Stage <0.0001 S100B <0.0001 0.002 2.6 (1.4–4.9) LDH <0.0001 0.008 2.3 (1.2–4.2) No significant financial relationships to disclose.
Efficacy and toxicity of concurrent rituximab plus infusional EPOCH in HIV-associated lymphoma: AIDS Malignancy Consortium Trial 034
Authors: A. M. Levine, J. Lee, L. Kaplan, L. F. Liebes, J. A. Sparano
Journal: Journal of Clinical Oncology (2008)

8527 Background: Prior studies have suggested promising activity for infusional EPOCH chemotherapy in HIV-associated lymphoma, but a higher risk of infection when rituximab (R) was added to standard CHOP chemotherapy. Methods: We performed a randomized phase II trial of rituximab (375 mg/m2/dose) given concurrently with each infusional EPOCH cycle (arm A) or weekly x 6 weeks after completion of EPOCH (arm B) in 106 eligible patients with HIV-associated B-cell lymphoma (74% diffuse large cell) (EPOCH=etoposide [E], prednisone, vincristine [V], cyclophosphamide, and doxorubicin [D]; Blood 2003; 101: 4653). Results: There was no significant difference in toxicity between arms, including grade 3–4 febrile neutropenia (16% vs. 15%), infection (27% vs. 29%), or deaths (10% vs. 7%). The null hypothesis (CR/CRu rate is 50% vs. alternative of 75%) is rejected for arm A (P=0.005; power 0.89) but not for arm B (P=0.394). In a post-hoc multivariate analysis that included arm (A vs. B), stage, CD4 < 100, elevated LDH, performance status, and antiretroviral therapy (yes/no), the only factors significantly associated with CR/CRu were arm A (odds ratio 2.41; P=0.04) and stage III-IV disease (odds ratio 0.28; P= 0.04). There was no significant difference in the mean steady state levels between arms A and B of E, V, or D (p= 0.66, 0.12, 0.77, respectively). Conclusions: We found no increased risk of severe toxicity with concurrent administration of R with EPOCH, and substantial activity for the combination. These findings support continued accrual to a phase III trial comparing R-CHOP vs. R-EPOCH in immunocompetent patients with intermediate grade B-cell lymphoma (C50303). Arm A: Concurrent R-EPOCH Arm B: Sequential EPOCH ⇒R No. Eligible 51 55 Median CD4% < 100/uL 181/uL/31% 194/uL/31% Age adjusted IPI (0–1 vs. 2- 3) 31%/69% 36%/64% CR/CRu Rate 35 (69%) 29 (53%) 90% Confidence Intervals, 2-sided (56%, 79%) (41%, 64%) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech™ BioOncology
Discussion
Authors: K T Weber
Journal: Cardiovascular Research (1997)

A stern wind embraced Denmark's capital this Saturday morning, January 15, 1972.Copenhagen had already been severely chilled by yesterday's passing of King Frederik IX, descendant of first King Gorm.Nonetheless, there was widespread confidence in Margrethe, Frederik and Ingrid's oldest, who today would become Denmark's first reigning Queen -an event made possible by a plebiscite in 1956 that unanimously amended the Act of Succession.Nicole Jacobsen, resident in internal medicine, considered Margrethe a symbol of national freedom and women's equality.Buoyed by this historic event, she began morning rounds.Mrs. T., a 52 year old, had been admitted with a two month history of weakness, constipation and headache.Typical rheumatoid erosions of hands and feet had appeared 20 years earlier; tender masses now involved affected joints.Blood pressure normal; aortic ejection murmur; and soft, tender masses of feet and hands.Elevated Ž .Ž .blood urea nitrogen BUN and creatinine Cr ; hypercalcemia, normal phosphorus, slightly elevated alkaline phosphatase, and increased urinary calcium excretion.Extensive periarticular calcifications on X-ray.Nicole ascribed respective symptoms and signs to hypercalcemia and calcification of dystrophic tissues.But why and why aortic sclerosis?Parathyroid function normal; no evidence of malignancy.From Mrs. T's daughter, Nicole uncovered that over the past 18 months mother had subscribed to an arthritic remedy handed down from Viking folklore.This daily regimen called for several tablespoons of cod liver oil served with large glasses of milk.Nicole made the diagnosis of vitamin D intoxication.Mr. S., a 67 year old farmer, presented with nausea and
Patterns of failure and outcomes in anal adenocarcinoma
Authors: R. J. Gonzalez, G. J. Chang, J. M. Skibber, B. W. Feig, C. Eng, N. Janjan, C. H. Crane, M. A. Rodriguez-Bigas
Journal: Journal of Clinical Oncology (2006)

13503 Background: Adenocarcinoma of the anal canal is a rare malignancy with an aggressive natural history. The purpose of this study is to evaluate the outcomes of a multidisciplinary approach in patients with anal adenocarcinoma. Methods: A retrospective review was performed of patients with anal adenocarcinoma identified from the M.D. Anderson Cancer Center (MDACC) tumor registry between 1983 and 2004. Distal rectal cancers were excluded by pathologic review. Patients were classified according to treatment type: chemoradiotherapy (CXRT) ± local excision or radical surgery (RS) ± chemoradiation. Overall survival, and patterns of failure were assessed. Results: 41 candidate patients were identified. Thirteen patients were excluded (10 misclassified, 3 no treatment or followup at MDACC). Of the remaining 30 patients, 27 had localized disease and were treated with curative intent. 26 patients received radiation, 23 of the 26 with concurrent 5-FU based chemotherapy. Eleven patients (41%) received additional 5-fluorouracil-based adjuvant chemotherapy following primary treatment. Twelve patients were in the CXRT treatment group and 15 were in RS (1 did not receive chemoradiation). Median follow-up was 28 months (range 5–195). Median overall survival for the entire cohort was 59 months with an actuarial 5-year survival of 47%. Rates of recurrence are shown in the table below. Three patients with local failure were treated with salvage abdominoperineal resection and all developed subsequent failure (2 distant, 1 local). The fourth patient refused surgery and subsequently developed disease progression. Conclusions: Adenocarcinoma of the anal canal has a poor prognosis and accurate histologic diagnosis should be pursued. Although limited, our experience demonstrates that the most common pattern of failure is distant. An aggressive multimodal approach results in good local control but improvements in chemotherapeutic strategies are needed. [Table: see text] No significant financial relationships to disclose.
Risk assessment model for first-cycle chemotherapy-induced neutropenia (CIN) among lung cancer (LC) patients: DELFOS study
Authors: J. Rifà, J. L. González Larriba, A. Casas Fernández de Tejerina, A. López Pousa, L. Febrer, A. Carrato
Journal: Journal of Clinical Oncology (2007)

9132 Background: CIN is common in LC patients (pts) who receive myelosuppressive chemotherapy and contributes to therapy induced morbidity and mortality therefore having strong impact both on health and on health care systems. The objective of the present research study is to determine a predictive model for first-cycle CIN in pts with LC in Spain. This will help to establish appropriate protocols in routine patient care, hence improving clinical decision making. Methods: Data were obtained from the DELFOS Study, a multicentre non-interventional prospective-cohort study in Spain. This study has completed enrolment and data are available for this planned analysis. To obtain the predictive logistic regression model (LRM), the hierarchical principle was followed as a way to enable results replication. The model was implemented for CIN defined as neutropenia grade = 3 (with or without body temperature = 38 C°). A receiver operating characteristics (ROC) Curve was used to determine the model's sensitivity and specificity. Results: A total of 210 pts with LC (86 % male; mean age: 63 yrs (SD: 10); ECOG = 2;) were included in 65 Spanish medical oncology health centres. A selection process of potentially relevant factors was performed among socio-demographic, clinical and biochemical parameters collected. The LRM obtained predicted the CIN at first-cycle (p Chi-sq &lt; 0.0005) through the following factors: baseline platelet count (BPC), baseline haemoglobin (Hb) and type of chemotherapy treatment. In that sense, lower BPC was associated with higher risk of CIN (p&lt;0.0005; OR=1.01; 95%CI (1.005, 1.016)) and the same happened with lower baseline Hb (p=0.017; OR=1.4; 95%CI (1.06, 1.8)). Pts in Platinum-based Chemotherapy showed higher risk of CIN compared to those in combination of Platinum and Taxane-based Chemotherapy (p=0.027; OR=5.5; 95%CI (1.2, 24.9). Inherent sensitivity and specificity of the equation were, respectively, 70.4% and 73.2%. Conclusions: A statistically significant risk predictive model for first-cycle CIN in pts with LC in Spain was implemented. Three predictive factors were identified. Baseline platelet count and baseline Hb were inversely associated with toxicity. Toxicity increased for pts with Platinum-based Chemotherapy regimens. No significant financial relationships to disclose.
Medication safety in cancer clinical trials: An analysis of medication error reports at a comprehensive cancer center
Authors: M. P. Kane, K. Fessele, J. Gordilis-Perez, S. Schwartz, S. Lisi, J. Nishioka, D. Vamos, A. Tan, R. Cunningham, S. Goodin
Journal: Journal of Clinical Oncology (2007)

6547 Background: Although medication errors comprise 10–25% of all medical errors, little is known concerning the occurrence or types of medication errors occurring while treating patients on a clinical trial. Therefore, we retrospectively reviewed the medication errors reported in patients enrolled on clinical trials at our center. Methods: As part of a multidisciplinary continuous quality improvement project, from January 2003 through December 2006, we collected voluntary reports of medication errors in adult and pediatric patients on clinical trials involving both oral and intravenous chemotherapy. All reports were classified prospectively regarding clinical trial involvement, severity category (A to I) per the National Coordination Council on Medical Error Reporting and Prevention, type, cause, and where in the medication use process the error occurred. Results: There were 163 reports involving patients treated on clinical trials. The most common errors were those corrected prior to reaching the patient in 68% of events (Category A&amp;B), while 31% reached the patient but did not result in harm (Category C&amp;D), with 1% resulting in temporary patient harm (Category E&amp;F). The most common type of errors were prescribing (66%), improper dose (42%), and omission errors (9%). Not following an institutional procedure or the protocol was the primary cause for these errors (39%), followed by the written order (30%), and poor communication involving both the healthcare team and the patient (26%). The processes where the errors initiated were in prescribing 47%, administration 10%, dispensing 6%, and monitoring 5%. Conclusion: Medication errors do occur in clinical trials, however the majority of these are corrected prior to reaching the patient or do not result in harm. Not following an institutional procedure or the protocol was the most common cause of error. This is most likely due to the protocol procedures differing from existing standards of care. Protocol-specific education through the Centralized Education and Training Service, a shared resource within our cancer center, addresses this issue enhancing the quality and safety of clinical trials through the education and training of healthcare professionals. No significant financial relationships to disclose.
Efficacy of 6 months treatment with PEG-interferon alpha-2b plus ribavirin (P/R) in patients infected with hepatitis C with genotype 1 of low viral load (G1LVL)
Authors: S. Zeuzem, Yves Horsmans, R Esteban-Mur, P Ferenci, J Sperl, J Cianciara, E Ibranyi, O Weiland, S Noviello, C Brass
Journal: Journal of Hepatology (2005)
Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors
Authors: Mark A Rosenberg, Jason Williams
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Image guided cryoablation of cancer destroys tumor tissue and can activate tumor-specific T cells by increasing the presentation of tumor antigens and causing the release of "Danger signals" to stimulate the immune system. However, the development of a systemic anti-cancer
Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors. A Spanish Germ Cell Group study
Authors: P. Maroto-Rey, X. García Del Muro, L. Paz-Ares, E. Alba, J. Sastre, A. Fernández-Aramburu, J. Aparicio, J. Terrassa, J. R. Germa
Journal: Journal of Clinical Oncology (2005)

4525
Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer.
Authors: M Benevolo, M Mottolese, M Cosimelli, M Tedesco, D Giannarelli, S Vasselli, M Carlini, A Garofalo, P G Natali
Journal: Journal of Clinical Oncology (1998)

PURPOSE Among the clinical factors with a pivotal role in the prediction of outcome for patients with gastric cancer, intraperitoneal (i.p.) microscopic dissemination may represent an important cause of recurrences, even in the early stages of the disease. In this context, the cytologic examination of intraoperative peritoneal washings may be essential to identify metastatic free cells, although a number of false-negative cases may be encountered. PATIENTS AND METHODS To determine whether immunocytochemical (ICC) methods that used a panel of three monoclonal antibodies (MoAbs), B72.3, AR3, and BD5, directed to gastric cancer-associated antigens can improve peritoneal cytology by providing more accurate prognostic indications, we immunocytochemically and morphologically evaluated 144 peritoneal washings sampled from patients surgically treated for gastric cancer. RESULTS The ICC analysis allowed the identification of metastatic free peritoneal cells in 35% of the patients, with a 14% improvement over routine cytopathology (P &lt; .0001). Furthermore, a 54-month survival analysis by Kaplan-Meier curves showed a statistically significant decrease in overall survival (OS) in patients with stages I through III disease with peritoneal microscopic disease detected morphologically and/or by ICC at the time of the primary surgery. CONCLUSION Our data indicate that the use of a combination of selected MoAbs may allow the identification of cytologically false-negative cases that provide valuable prognostic information. This may be useful to stratify patients on more adequate therapeutic trials.
Triple-negative phenotype of breast cancer and its association with poor prognostic factors
Authors: M. A. Tohfe, N. Chamseddine, F. Ghandour, H. Chmaitelly, M. Khatib, W. Saliba
Journal: Journal of Clinical Oncology (2008)

22134 Background: Breast cancer is a heterogeneous disease composed of many phenotypic subgroups. Triple-negative (TN) phenotype (negative for estrogen receptor, progesterone receptor, and HER2) is a high risk subgroup, classically known to be associated with poor prognostic factors. Methods: The histology of 244 breast cancers, diagnosed in our institution between 2003–2006, was reviewed and categorized, based on HER2 overexpression and hormonal receptor status. We identified at first two phenotypic subgroups: “Triple-negative” and “all Others”. We examined differences between these two subgroups in relation to the following variables: age, tumor size, axillary nodal (AN) involvement, histological and nuclear grade. Fisher exact test and Mann Whitney tests were used to examine the statistical association between each subgroup and these variables. Results: Of the 244 cases, 39 (16%) were of “TN” phenotype as compared to 205 with the phenotype “Others”. Both groups were similar with respect to Age, Tumor size, and AN involvement, but “TN”cases had statistically significant more histological grade III and nuclear grade III comparing to “all Others.” Conclusions: There is a predominance of more aggressive histological features in TN breast cancers comparing to “all Others” phenotype. The other prognostic factors (age, tumor size and AN) were similar in the 2 groups. Further studies are needed to categorize these cases by DNA microarray and immunohistochemical profiling. Phenotype Subgroup TN All Others P Value Age 53 years 54 years 0.99 Tumor Size 2.35 cm 2.54 cm 0.53 AN Involvement 50% 49.7% 0.97 Histological Grade III 72% 28% < 0.001 Nuclear Grade III 92% 47% < 0.001 No significant financial relationships to disclose.
Phase II trial of temozolomide as first-line treatment for patients with advanced gynecological sarcoma: A Spanish Group for Research on Sarcomas (GEIS) and Spanish Ovarian Cancer Research Group (GEICO) study
Authors: X. Garcia Del Muro, A. Poveda, J. M. Buesa, J. Martinez Trufero, L. M. De Sande, E. Calvo, P. Escudero, A. Lopez Pousa, X. Fabregat, A. Casado
Journal: Journal of Clinical Oncology (2006)

9570 Background: Temozolomide (TMZ) as an extended schedule showed activity in the subgroup of patients (pts) with pretreated gynecological sarcoma (GS) in a prior phase II study (Cancer 2005;104:1706) as well as in a series of GS pts treated in a compassionate use program (Proc ASCO 2005;9030). The purpose of the present study was to assess the activity of TMZ as first-line chemotherapy in pts with GS. Methods: Pts with non-previously treated advanced GS and non-irradiated measurable lesions were eligible for this phase II study. TMZ was administered orally at a dose of 75 mg/m2/day continuously for 6 weeks, every 9 weeks. The study was conducted using a Simon’s two-stage design. The initial planned sample size was 25, but after an amendment, this was increased to include 25 pts with leiomyosarcoma (LMS) histology. Primary endpoint was response rate (RECIST). Results: From October 02 to September 05, 33 pts were included at 16 centers. At present, 32 pts are evaluable (1 too early). Median age was 59 (39–75). Primary tumor sites were uterus (31) and ovary (2). Histologic types were: LMS (28), mixed mullerian tumor (3), endometrial stromal sarcoma (ESS) (2). Histologic grade: III:16, II:6, I:2, unknown:9 pts. PS: 0:12, 1:15, 2:6 pts. A total of 57 cycles were administered (median 2, range 1–3). Toxicity (pts): thrombocytopenia G-IV:2, GIII:1; neutropenia G-IV:1; nausea G-III:2, G-II:5; vomiting G-III:2, G-II:6; stomatitis G-III:1, G-II:2; asthenia G-III:1, G II:5. There were 3 CR, 3 PR and 6 SD, giving an overall response rate of 19% (95% CI, 5–32%). Responses were seen in LMS (5) and ESS (1) and lasted 4+, 6, 7+, 7+, 9+ and 17+ months. Median time to progression was 3.3 months (95% CI, 1.7–4.9). Conclusions: TMZ at this extended schedule was active against GS, producing in some pts long-lasting responses, and might be a well-tolerated alternative in selected pts, warranting further investigation. No significant financial relationships to disclose.
Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)
Authors: Martin JS Dyer, Andrew Grigg, Marcos González, Martin Dreyling, Simon A. Rule, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, Paula Marlton
Journal: Blood (2012)
Phase II study of CDDP + S-1 combination chemotherapy for advanced and recurrent gastric cancer
Authors: A. Tsuji, S. Morita, Y. Shima, Y. Nishioka, T. Horimi, T. Shirasaka
Journal: Journal of Clinical Oncology (2004)

4148 Background: S-1 is highly active for gastric cancer with a response rate of 40% or higher in single agent studies and we are showed synergism with low dose of CDDP in Phase I study (B. Nakata, A. Tsuji et al. Clinical Cancer Research 2004 in press). The aim of this study was to assess the efficacy and safety of CDDP + S-1 (S-1/P) combination therapy for advanced and recurrent gastric cancer. Patients and Methods: The eligibility required; histologically proven gastric cancer with measurable metastatic lesions, PS 0–2, age < 75, adequate organ functions, and written informed consent. 15 patients were enrolled in this study (8 patients were naive cases and 7 patients were previously treated cases, and they were treated with a combination chemotherapy regimen consisting of S-1, 80 mg/m2 (divided into 2 doses) daily, plus CDDP in a dose of 3 mg/ m2 by intravenous infusion daily for 5 days a week followed by two days off for inpatients, and in a dose of 6 mg/ m2 by intravenous infusion twice a week for outpatients. One course consisted of treatment for 4 weeks followed by a 2-week rest period, and an average of 4 courses was administered. Results: The antitumor effect consisted of a CR in 1 case, PR in 8 cases and SD in 3 cases. The efficacy rate was 75.0% (9/12), and MST was 12.2 months. There was no difference in efficacy rate between the naive cases and the previously treated cases. The principal adverse reactions were myelosuppression and gastrointestinal symptoms, and the incidence of Grade 3 or more adverse reactions was 33.3% (5/15). Conclusions: Preliminary response results are very promising associated with mild toxicity, and it appeared to be a useful method of treatment that can be used in the outpatient clinical as well. No significant financial relationships to disclose.